Brokerages Set Krystal Biotech, Inc. (NASDAQ:KRYS) Target Price at $228.14

Krystal Biotech, Inc. (NASDAQ:KRYS) has been assigned a consensus recommendation of “Moderate Buy” from the eight analysts that are currently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $228.1429.

KRYS has been the topic of a number of research reports. Citigroup raised their target price on shares of Krystal Biotech from $166.00 to $198.00 and gave the company a “neutral” rating in a research note on Tuesday, November 4th. HC Wainwright reissued a “buy” rating and issued a $240.00 price objective on shares of Krystal Biotech in a research report on Monday, September 15th. Chardan Capital upped their target price on Krystal Biotech from $216.00 to $220.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Guggenheim set a $224.00 target price on Krystal Biotech and gave the company a “buy” rating in a research note on Friday, October 17th. Finally, Bank of America boosted their price target on Krystal Biotech from $182.00 to $255.00 and gave the stock a “buy” rating in a research report on Friday, October 17th.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the completion of the sale, the insider directly owned 1,413,711 shares in the company, valued at $311,242,613.76. This trade represents a 1.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 13.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Krystal Biotech

A number of institutional investors have recently made changes to their positions in the business. Brooklyn Investment Group grew its position in shares of Krystal Biotech by 291.7% during the first quarter. Brooklyn Investment Group now owns 141 shares of the company’s stock worth $25,000 after buying an additional 105 shares in the last quarter. Hantz Financial Services Inc. raised its holdings in Krystal Biotech by 8,950.0% in the second quarter. Hantz Financial Services Inc. now owns 181 shares of the company’s stock valued at $25,000 after acquiring an additional 179 shares in the last quarter. Bessemer Group Inc. boosted its stake in Krystal Biotech by 106.9% during the 3rd quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock valued at $26,000 after acquiring an additional 77 shares during the last quarter. Twin Tree Management LP acquired a new position in Krystal Biotech during the 1st quarter worth $29,000. Finally, AdvisorNet Financial Inc bought a new stake in shares of Krystal Biotech in the 3rd quarter worth about $30,000. 86.29% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Price Performance

Shares of NASDAQ:KRYS opened at $240.80 on Wednesday. The business has a 50-day moving average of $209.37 and a two-hundred day moving average of $170.35. The firm has a market capitalization of $6.98 billion, a PE ratio of 36.10 and a beta of 0.48. Krystal Biotech has a 12 month low of $122.80 and a 12 month high of $248.60.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, November 3rd. The company reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $1.54. Krystal Biotech had a return on equity of 19.36% and a net margin of 53.30%.The business had revenue of $97.80 million during the quarter, compared to analysts’ expectations of $93.72 million. As a group, research analysts anticipate that Krystal Biotech will post 6.14 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.